IceCure Medical

IceCure Medical Ltd. is an Israeli medical device company that specializes in liquid-nitrogen-based cryoablation therapy systems. These systems are designed to treat both benign and malignant tumors by freezing them, offering a minimally invasive alternative to traditional surgical tumor removal. Procedures can be performed quickly in an office or CT room, making them safer and less disruptive for patients. The company's flagship product, ProSense®, utilizes ultra-cold temperatures to destroy tumors through a freeze-thaw-freeze cycle. This method effectively eliminates tumors without surgery, focusing primarily on treating tumors in the breast, kidney, bone, and lung. IceCure's technology is backed by extensive clinical research, including a significant trial that demonstrated high safety and efficacy rates, with most patients resuming daily activities within 48 hours. IceCure Medical markets its cryoablation systems globally, targeting hospitals and cancer treatment centers. The company is actively pursuing regulatory approvals, including engagement with the U.S. FDA for marketing authorization of ProSense® in early-stage low-risk breast cancer.

• Employees 64
• Founded 2006
• Annual Revenue $3273000
• Total Funding $41000000